NMR studies of an immunomodulatory benzodiazepine binding to its molecular target on the mitochondrial F 1 F 0 -ATPase by Stelzer, Andrew C. (Andrew Corbet) et al.
NMR Studies of an Immunomodulatory Benzodiazepine Binding to its
Molecular Target on the Mitochondrial F1F0-ATPase
Andrew C. Stelzer,1 Richard W. Frazee,2 Chad Van Huis,3 Joanne Cleary,2
Anthony W. Opipari Jr.,4 Gary D. Glick,2 Hashim M. Al-Hashimi1
1 Department of Biophysics, University of Michigan, Ann Arbor, MI 48109
2 Department of Chemistry, University of Michigan, Ann Arbor, MI 48109
3 Lycera Corporation, 46701 North Commerce Center Drive, Plymouth, MI 48170
4 Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI 48109
Received 13 August 2009; revised 24 August 2009; accepted 24 August 2009
Published online 18 September 2009 in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/bip.21306
This article was originally published online as an accepted
preprint. The ‘‘Published Online’’ date corresponds to the
preprint version. You can request a copy of the preprint by




z-423 is a 1,4-benzodiazepine that potently sup-
presses disease in autoimmune mice by selectively
killing pathogenic lymphocytes.1,2 Affinity-based
screening of a phage-display human cDNA expres-
sion library identified the oligomycin-sensitivity
conferring protein (OSCP), a component of the mitochon-
drial F1F0-ATPase, as the molecular target for Bz-423.
3 Bind-
ing of Bz-423 to the OSCP in the context of intact enzyme
inhibits both synthesis and hydrolysis of ATP.3,4 Consistent
with modulation of F1F0-ATPase activity, Bz-423 increases
the generation of superoxide from the mitochondrial respira-
tory chain and this reactive oxygen species, rather than
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ABSTRACT:
Bz-423 is an inhibitor of the mitochondrial F1F0-ATPase,
with therapeutic properties in murine models of immune
diseases. Here, we study the binding of a water-soluble
Bz-423 analog (5-(3-(aminomethyl)phenyl)-7-chloro-
1-methyl-3-(naphthalen-2-ylmethyl)-1H-
benzo][e][1,4]diazepin-2(3H)-one); (1) to its target
subunit on the enzyme, the oligomycin sensitivity
conferring protein (OSCP), by NMR spectroscopy using
chemical shift perturbation and cross-relaxation
experiments. Titration experiments with constructs
representing residues 1–120 or 1–145 of the OSCP reveals
that (a) 1 binds to a region of the protein, at the
minimum, comprising residues M51, L56, K65, V66,
K75, K77, and N92, and (b) binding of 1 induces
conformational changes in the OSCP. Control
experiments employing a variant of 1 in which a key
binding element on the small molecule was deleted; it had
no perturbational effect on the spectra of the OSCP,
which indicates that the observed changes with 1
represent specific binding interactions. Collectively, these
data suggest that 1 might inhibit the enzyme through an
allosteric mechanism where binding results in
conformational changes that perturb the OSCP-F1
interface resulting in disrupted communication between
the peripheral stalk and the F1-domain of the enzyme.
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changes in ATP concentration, is the signal that initiates apo-
ptosis.5,6
The OSCP is a 213 amino acid long protein (including the
mitochondrial leader sequence) that is conserved among
mammals and is not present in other ATPases.7 The OSCP
along with subunits b, d, and F6 form the peripheral stalk in
mammalian F1F0-ATPases.
8 The stalk links the integral mem-
brane F0 component of the enzyme with its soluble catalytic
F1 domain, which is located in the mitochondrial matrix.
The peripheral stalk is believed to act as a stator, holding the
F1 a3b3 hexamer static while the central stalk (cdec10)
rotates.9,10 To function properly, the stalk subunits must act
in concert with one another; while the peripheral stalk subu-
nits do not need to move in relation to one another during
catalysis, disrupting the connections between the subunits
disrupts coupling between F0 and F1.
11 In addition, the stalk
must be anchored at each end for proper function: the trans-
membrane domain of subunit b holds the stalk in the mito-
chondrial membrane, while the N-terminal end of the OSCP
sits on top of the a3b3 hexamer with the C-terminus pro-
truding almost 100 Å along the surface of F1 towards F0.
12
The N-terminal tails of the a-subunits are critical for binding
to OSCP.13
The structure of a 134-amino acid long N-terminal frag-
ment of the d-subunit from E. coli, the bacterial homolog of
the bovine OSCP, has been studied by NMR spectroscopy.14
The protein adopts a 6-helix bundle with a disordered C-ter-
minus. NMR studies using the N-terminal domain of the bo-
vine OSCP (OSCP-NT, residues 1–120) reveals a similar
fold.15,16 Binding experiments with peptide fragments from
the N-termini of F1 a-subunits suggests that the interaction
site on OSCP-NT comprises a hydrophobic groove between
helices I and V. Hence, this interface, which is essential for
the rotary mechanism of the enzyme, probably consists of
helix-helix interactions.
Because Bz-423 does not bind at the active site of enzyme,
we hypothesized that it may bind at, or near the F1-OSCP
interface where it can perturb one or more of the conforma-
tional transitions associated with the rotary (binding-
change) mechanism of catalysis.4 To gain support for this hy-
pothesis, we studied the binding of water soluble Bz-423 ana-
logs (Figure 1) with OSCP constructs representing amino
acids 1–120 and 1–145 by NMR spectroscopy using chemical
shift perturbation and cross-relaxation experiments to local-
ize the binding site. Our data identified a recognition site
near the F1-OSCP interface and a conformational change in
the protein upon drug binding. Collectively, these data sug-
gest that Bz-423 like inhibitors may function in an allosteric




Benzodiazepines 1 and 2 were synthesized and characterized as pre-
viously described.15 Samples of both compounds used in the NMR
titration experiments were[95% pure.
Plasmid Construction
A 360-base-pair long insert encoding a truncated bovine OSCP, con-
taining amino acids 1–120, was prepared via PCR using forward (50-
CACCATGTTTGCCAAGCTTGTGAGGCC-30) and reverse (50-CTA
AACTGTGCATGGTACTTCTCC-30) oligonucleotide primers (25 lM
each) in the presence of dNTPs (0.5 mM), pOSCP (1 ng), PFU Turbo
DNA polymerase (3–5 U; Stratagene, La Jolla, CA), and 13 PFU
Turbo DNA polymerase buffer. PCR conditions consisted of 30 s at
FIGURE 1 Chemical structure of (a) Bz-423 and the molecules used in this study: (b) 5-(3-(ami-
nomethyl)phenyl)-7-chloro-1-methyl-3-(naphthalen-2-ylmethyl)-1H-benzo[e][1,4]diazepin-2(3H)-
one (1) and (c) (aminomethyl)phenyl)-7-chloro-1-methyl-1H-benzo[e][1,4]diazepin-2(3H)-one
(2). Protons of 1 that were saturated in cross-relaxation experiments are labeled. Based on prior
structure-reactivity studies as a guide, 1 was designed to replace the critical phenolic proton with an
ammoninum group to enhance aqueous solubility. The activity of 1 in enzyme and cellular assays is
comparable. Removing the naphthyl group in 2 abolishes all activity against the enzyme.
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948C, 30 s annealing at 558C, and a 1 min extension at 728C for 31
cycles.17 A 435-base-pair long insert encoding a truncated bovine
OSCP containing amino acids 1–145 was prepared in a similar man-
ner using the same forward oligonucleotide primer as above together
with a reverse (50-CTGGCCTTTACTTAGGAAGCTCTTCAGG-30) oli-
gonucleotide primer. The PCR products were purified using a Qiagen
(Valencia, CA) PCR Clean Up kit following the manufacturer’s
instructions. Both inserts were cloned into expression vectors provided
in the TOPO 10 kit following the manufacture’s instructions (Invi-
trogen, Carlsbad, CA). The OSCP 1–120 insert was ligated into
pCRT7/NT-TOPO that contains both an ExpressTM Epitope coding
sequence and a hexa-his tag, placing the OSCP 1–120 coding region
C-terminal to these sequences. The OSCP 1–145 insert was ligated
into pCRT7/CT-TOPO, which contains both a V5 Epitope coding
sequence and a hexa-his tag, placing the OSCP 1–145 coding region
N-terminal to these sequences. Thus, OSCP120 contains an N-termi-
nal hexa-his tag connected by the linker sequence GMASMT-
GGQQMGRDLYDDDDKDPTL, while the OSCP145 construct con-
tains a C-terminal hexa-his tag connected by the linker sequence
KGNSKLEGKPIPNPLLGLDSTRTG. Primary structures for all OSCP
constructs are shown in Supporting Information Figure S1. Ligation
products were transformed into TOP-10 cells and selected on LB-
ampicillin (50 lg/mL) plates. Colonies were screened for inserts via
PCR using mini-prep plasmid DNA and both the forward and reverse
T7 primers. The presence of the correct inserts was confirmed by auto-
mated DNA sequencing (Sequencing Core Facility, University of
Michigan, Ann Arbor, MI).
Growth and Expression of OSCP Constructs
OSCP constructs pCRT7/NT-OSCP120 and pCRT7/CT-OSCP145
were transformed into One Shot BL21(DE3) pLysS (Invitrogen, Carls-
bad, CA) using the manufacturer’s procedure. Individual colonies
were picked immediately to inoculate 1–10 mL LB overnight cultures
supplemented with ampicillin (200 lg/mL). Cultures were incubated
at 378C with rotary shaking at 250 rpm. One-liter cultures containing
either Spectra 9-N ([98% 15N), Spectra 9-CN ([98% 15N, [98%
13C, or Spectra 9-dCN ([97% D2O, [98%
15N, [98% 13C) media
(Spectra Stable Isotopes, Columbia, molecular dynamics (MD)), were
supplemented with ampicillin (200 lg/mL) and inoculated with the
overnight culture. Cultures were grown at 378C with rotary shaking at
250 rpm until A595 reached 0.6–1 (Spectra 9-dCN required double the
growth time compared to the other media) at which point cultures
were removed to 48C while the rotary shaker temperature was brought
down to 208C using a heat exchanger over a period of 1 h. IPTG was
added to a final concentration of 0.02 mM. Growth and expression
continued for 20 h at 208C. Cell pastes were harvested via centrifuga-
tion in a Beckman JLA8.1 at 6000g for 10 min at 48C. Cell pastes were
resuspended in ice-cold Nickel NTA buffer (25 mL; 50 mM Tris-HCl
pH 8, 300 mM NaCl, 0.001% phenylmethanesulfonyl fluoride, and
Roche Complete protease inhibitors w/o EDTA as per manufacturers
instruction). The suspension was transferred to a 50 mL Falcon tube
on ice and stored at –808C.
Purification of OSCP 120NT (His Tag) and
OSCP 145CT (His Tag)
Cell paste was thawed at room temperature and placed immediately
on ice. The suspension was transferred to a 50 mL beaker on ice and
sonicated using the standard horn (set at output 5 8.5) for 6 20-s
long intervals between which was a 2-min long rest on ice to dissipate
heat. After sonication, the mixture was transferred to two Beckman
JA25.5 centrifuge tubes and centrifuged at 21,000 rpm at 48C for
45 min. The soluble extract was loaded (0.5 mL/min) onto a Ni-NTA
affinity column (1 cm diameter 3 5 cm long) equilibrated in Nickel
NTA Buffer at 48C. The column was washed with Nickel NTA Buffer-
25 mM imidazole (25 mL), and protein was eluted with Nickel NTA
Buffer-250 mM imidazole (25 mL). Fractions of about 1 mL were col-
lected and those from fractions 3–14 were direct placed into snakeskin
dialysis tubing (7000 MWCO, Pierce, Rockville, IL) immersed in of
OSCP Buffer (4 L; 50 mM Tris-Cl pH 8, 30 mM NaCl, 1 mM EDTA,
5 mM b-mercaptoethanol). Complete protease inhibitors (with or
without EDTA) were added following the manufacturer’s instructions,
directly to the fractions in the dialysis bag. Following overnight dialy-
sis at 48C with stirring, the dialysate was cleared by centrifugation
using a Beckman JA 25.5 rotor for 20 min at 21,000 rpm and 48C. The
clarified extract was loaded into a ÄKTA prime super loop (50 mL) at
48C and injected at 1.3 mL/min onto a 5 mL HiTrap SpHP column
(Pharmacia) equilibrated in at least five volumes of modified OSCP
Buffer (50 mM Tris-Cl pH 8, 30 mMNaCl, 1 mM EDTA, 0.001% phe-
nylmethanesulfonyl fluoride, Roche Complete protease inhibitors w/o
EDTA, 5 mM b-mercaptoethanol; MOB) at 48C. The column was
washed with two bed volumes of the same buffer and then eluted with
a 75 mL linear gradient (MOB and MOB 1 500 mM NaCl) at 1 mL/
min while collecting 1 mL fractions. OSCP 120NT eluted in a sharp
band centered around 250 mM NaCl, while OSCP 145CT eluted in a
similar manner at 280 mM NaCl.
NMR Spectroscopy
All NMR experiments were performed at 258C unless indicated other-
wise using an Avance Bruker 600 MHz spectrometer equipped with a
5 mm triple-resonance cryogenic probe. NMR spectra were processed
and analyzed using NMRPipe and SPARKY 3.18,19 The NMR buffer
consisted of 90/10% H2O/D2O containing 50 mM Tris, 5 mM KCl,
5 mM b-mercaptoethanol, 0.001% PMSF, and protease inhibitor
cocktail at pH  7. For cross-relaxation experiments, a 2H/15N labeled
OSCP120 (0.3 mM) sample was used in an NMR buffer consisting of
90/10% D2O/H2O containing deuterated TRIS (50 mM) and deuter-
ated b-mercaptoethanol (5 mM) at pH  7 without PMSF and prote-
ase inhibitor cocktail to minimize spectral overlap with 1. 93% of the
OSCP120 backbone amides could be assigned based on a previous
NMR study (BMRB entry 6564) (Supplementary Information Figure
S2).20 The OSCP120 resonances in OSCP145 were assigned by over-
laying spectra and using standard triple resonance experiments on a
doubly labeled (13C/15N) OSCP145 sample (0.5 mM).
Two-dimensional (2D) 1H-15N HSQC spectra of 15N labeled
OSCP were recorded following incremental addition of 1 from a
stock solution (20 mM) in NMR buffer for protein:ligand ratios of







where dH and dN are the proton and nitrogen amide chemical shift
values in ppm. Weighted average chemical shifts [0.01 ppm were
considered significant.
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Cross-relaxation experiments were performed at 148C to
improve cross-relaxation efficiency by modifying a 2D 1H-15N
HSQC experiment from the Bruker pulse program library
(hsqcfpf3gpphwg).21 A 1.8 s adiabatic Wurst pulse was applied fol-
lowing a predelay of 1.4 s for saturating one of three different ligand
proton resonances (protons 7, 10, and 24; Figure 1) with a total sat-
uration bandwidth of 30 Hz.22 An additional reference experiment
was also recorded with off-resonance (–50 ppm) saturation. Each
experiment required 23 h of acquisition time. Peak intensity errors
were calculated using NMRPipe and ranged between 4% and
19%.18,19 Cross-relaxation intensity ratios were calculated by taking
the ratio of peak intensities measured with on-resonance (Isat) and
off-resonance (Io) saturation. Only well-resolved resonances with a
signal-to-noise ratio [10 were analyzed. Chemical shift perturba-
tions and cross-relaxation results were mapped onto OSCP struc-
tures and visualized using Pymol.23
RESULTS
Mapping the Binding of 1 to OSCP120 Using
Chemical Shift Perturbation
In a first group of studies, we attempted chemical shift per-
turbation experiments using full-length, 15N labeled OSCP
(OSCP190) (Supporting Information Figure S1). However,
the 2D HSQC spectra of OSCP190 were intractable due to
aggregation identified by uniform reduction in NMR signal
intensities.16,20 We subsequently prepared two truncated con-
structs for binding measurements. The first protein com-
prised residues 1–120 (OSCP120) and has been studied pre-
viously by NMR, and the second construct contained resi-
dues 1–145 (OSCP145). Titration of 1 into 15N labeled
FIGURE 2 Chemical shift perturbations from titrations of 1 and 2 onto OSCP120 are shown in
(a) and (b), respectively. Free OSCP120 (red), 1:2 OSCP120:1,35 1:4 OSCP120:1 (blue), and 1:4
OSCP120:2 (gray) spectra are shown. Only resonances that exhibited significant chemical shift per-
turbations are labeled in (a), and peaks labeled in (b) are for comparison purposes. Weighted average
of chemical shift perturbations (c) are color coded to match coloring on the OSCP120 structure (d)
with blue representing resonances that showed no significant perturbation and red showing those
resonances with shifts greater than the threshold of 0.01 ppm. Residues that could not be monitored
are colored in gray and the shoulder region is circled in (d). Protein precipitation was observed at 1:8
OSCP:ligand ratios, which precluded further increasing the ligand concentration.
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OSCP120 at protein:ligand ratios of 1:1, 1:2, 1:4, and 1:8 led
to chemical shift perturbations that suggest rapid exchange
on the NMR timescale consistent with micromolar affinity,
which agreed with previous data for Bz-423 (Figures 1 and 2
and Supplementary Information Table S1).4 To assess the sig-
nificance of the OSCP chemical shift perturbations, a second
set of titration experiments were conducted using an analog
lacking the naphthalene substituent 2. This analog possesses
no activity in the F1F0-ATPase or cell-based assays, (data not
shown) and therefore, we hypothesized should not to bind to
the protein. Indeed, chemical shift perturbations were not
observed in titration experiments with 2 (Figure 2), indicat-
ing that the perturbations observed with 1 reflect specific
binding interaction(s) that presumably are related to its in-
hibitory activity.
The chemical shift perturbations induced by 1 were dis-
tributed at different sites within the OSCP120 construct
(Figure 2). This observation suggests that 1 either binds at
multiple sites and/or binding at one site causes conforma-
tional changes elsewhere in the protein. The range of inten-
sities observed in OSCP120 suggests that the protein is highly
flexible and potentially prone to ligand-induced (allosteric)
conformational changes. In addition, previous studies of Bz-
423 suggest a 1:1 stoichiometry upon binding to the F1F0-
ATPase.4 Collectively, these observations are consistent with
ligand-induced conformational changes away from the bing-
ing site.
The chemical shift perturbations caused by 1 fall in three
general regions of OSCP120; one is located between helices
III, IV, and V (‘‘shoulder’’) and includes residues M51, L56,
K65, V66, K75, K77, T82, S83, and N92; the second is located
at the C-terminal tails of helices I and VI (‘‘tail region’’) and
includes residues V111, R113, V116, C118, and T119; a third
potential locus is located between the ‘‘tail’’ and ‘‘shoulder’’
regions (Figure 3). Interestingly, the latter region includes
residues A25 and L88, which were previously shown to inter-
act directly with the a peptide mimicking the F1 domain of
the F1F0-ATPase.
16,20
To confirm the data obtained with OSCP120, we used a
second OSCP construct comprising 145 amino acids
(OSCP145). Unlike the OSCP190, this truncated protein did
not aggregate and was amenable to chemical shift perturba-
tion experiments with 1. Comparing the OSCP120 and
OSCP145 spectra reveals that the majority of the OSCP120
resonances are not altered due to the additional 25 amino
acids in the OSCP145 construct (Supplementary Information
Figure S3). Not surprisingly, residues that showed significant
differences between the two constructs were primarily
located at the N- and C-termini. However, chemical shift dif-
ferences were observed at helix V, which interacts with the F1
peptide.16 This region, which also undergoes perturbations
with 1, may be subject to allosteric conformational perturba-
tions that could be important in mediating OSCP interac-
tions with the F1F0-ATPase F1 domain.
4
Titration with 1 induced chemical shift perturbations in
OSCP145, whereas 2 did not (Supplementary Information Figure
S4). Several resonances from the shoulder (M51, L56, K65, V66,
K75, and N92) and middle region of the protein (A25, E36, L40,
K47, I102, and F105) that overlaid in OSCP120 and OSCP145
showed similar perturbations with 1, including A25, which inter-
acts with the F1 helix (Supplementary Information Figure S3).
Many residues in the shoulder region (E48, A52, K67, T73, S79,
S83, E91, and R94) also showed larger perturbations with 1 in
OSCP145 compared to OSCP120. By contrast, some of the per-
turbations observed in the ‘‘tail’’ (residues V116 and C118), mid-
dle (L88), and shoulder (T82) regions were less pronounced in
OSCP145. Taken together, these data indicate that the shoulder
region is the most probable binding site for 1 on OSCP.
Probing the OSCP Ligand-Binding Site
by Cross-relaxation
Because chemical shift perturbations can arise from binding
and/or conformational changes, cross-relaxation experiments
were employed to localize the binding site of 1 on
OSCP120.24 For these studies, 2D HSQC spectra of OSCP
following saturation of specific 1H resonances in 1, and an
equivalent reference spectrum with off-resonance (–50 ppm)
saturation were measured. A reduction in OSCP resonance
FIGURE 3 The structure of OSCP120 (PDB ID# 2BO5) is shown
with helices, termini, shoulder, and tail regions labeled.
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intensities in the on-resonance (Isat) versus off-resonance (Io)
experiment indicates cross-relaxation processes due to prox-
imity of ligand protons to OSCP amide protons resulting
from a specific binding interaction.
Although the cross-relaxation experiment is inherently
insensitive since it recorded in 90% D2O to avoid saturation
of the water resonance, and despite the limited solubility of
OSCP, which further limited sensitivity, 32 well-resolved res-
onances with sufficient signal:noise were observed in the
OSCP1201 complex. As shown in Figure 4, significant in-
tensity reductions ([20%) are observed for a number of resi-
dues. The majority of these residues (R41, K50, A52, V60,
FIGURE 4 Intensity ratios (Isat/Io) from cross-relaxation experiments saturating protons at posi-
tions (7), (10), and (24) and their average is shown in (a). The 32 residues that were measured are
color coded according to intensity reductions with those showing no significant reduction in inten-
sity colored in blue and resonances showing intensity reductions greater than the threshold cutoff of
0.8 colored in red. The same color scheme is used in (b) with labeled residues being those that
showed significant intensity reductions in any of the three sets of cross-relaxation data. Residues that
could not be monitored are colored in gray and the shoulder region is circled in (b).
90 Stelzer et al.
Biopolymers
V66, S79, I86, and N87) fall in the ‘‘shoulder’’ region. Cross-
relaxation to residues in the tail region (K28, K31, and V111)
was also observed and V111 corresponds to a residue for
which significant chemical shift perturbations upon titration
of 1 were measured. However, this site is most likely cryptic
and only present in the truncated OSCP constructs because
the perturbations are diminished or otherwise significantly
altered in OSCP145. Taken together, the chemical shift per-
turbation and cross relaxation studies are consistent with a
unique binding site for 1 on the OSCP.
DISCUSSION
Inhibitors of the mitochondrial F1F0-ATPase are powerful
tools for probing the structure and function of the enzyme
and like Bz-423, some have therapeutic potential.25–27 A
diverse group of molecules inhibit the enzyme by binding
within the F1 domain. Representative compounds here
include the antibiotics aurovertin and efrapeptin, phyto-
chemicals like resveratrol, and the naturally occurring pep-
tide inhibitor, IF1. Aurovertin binds to bTP and bE states of
the enzyme and is thought to function by preventing closure
of the interfaces necessary for catalytic cycling between subu-
nit conformational states.4,28–31 Efrapeptin interacts with the
c and bE subunits where it can block recharging after cataly-
sis.28 Similarly, resveratrol inhibits the F1F0-ATPase by bind-
ing between the c and bTP subunits where it can block the
rotation of the c subunit so that the catalytic cycle cannot
progress.32 IF1 inhibits ATP hydrolysis when the ability of
the enzyme to synthesize ATP is compromised. IF1 is
thought to function by hindering the closure of the aDP-bDP
catalytic interface thereby blocking ATP hydrolysis.33 Several
molecules such as the macrolide oligomycin inhibit the F1F0-
ATPase by binding to the embedded F0 domain.
8 Biochemi-
cal studies suggest that oligomycin binding blocks the flow of
protons through the c-subunit.
Here, we used NMR spectroscopy to investigate binding of
a water-soluble Bz-423 analog to OSCP constructs of varying
length in an effort to define the binding site for these inhibitory
benzodiazepines on the protein. The chemical shift perturba-
tion data on both OSCP120 and OSCP145 together with cross-
relaxation data for OSCP120 suggest that 1 most likely binds
to the shoulder region in a pocket defined by residues M51,
L56, K65, V66, K75, K77, and N92. The peak intensities of
unbound OSCP120 suggest that both the shoulder and tail
regions are more flexible relative to the rest of the protein,
potentially allowing for local rearrangements to occur upon
ligand binding (data not shown). While we cannot rule out a
possible secondary binding site in OSCP120 involving the tail
region, this interaction was diminished in OSCP145, indicating
that interactions at this site are not likely relevant and probably
result as a consequence of the truncation only present in the
120-amino acid long OSCP construct.
Several residues show chemical shift perturbations in the
titration experiments but no significant cross-relaxation,
which is most consistent with conformational changes on
binding to 1. These residues include A25 and L88, which are
thought to directly interact with the F1.
16,34 L88 along with
other residues in its vicinity also shift when comparing free
OSCP120 and OSCP145, even though the 25 amino acids are
added to the C-terminal end of OSCP145. On the basis of
the NMR structure of OSCP120, L88 is distant from the
additional 25 amino acids. These data further support the
hypothesis that this region of the OSCP is susceptible to con-
formational changes, which may be important for the func-
tion of the protein in the fully assembled enzyme and the ac-
tivity of Bz-423 like inhibitors.
On the basis of our data, we propose an allosteric model
for the inhibitory action of 1. Binding of 1 to the shoulder
FIGURE 5 Proposed allosteric model where binding of 1 causes conformational rearrangements
(at helices I, V, and VI) in OSCP thus altering OSCP-F1 interactions. Stars indicate site for the OSCP-
F1 peptide interaction that were perturbed during titration experiments with 1.
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region of OSCP results in conformational rearrangements at
a site that contacts the F1 domain of F1F0-ATPase, which
interferes with the rotary mechanism of catalysis (Figure 5).
Allosteric communication between 1 and F1 binding sites
may be achieved by relative twisting motions of helices I and
VI. Such a structural rearrangement could explain the pertur-
bations observed in the middle region linking 1 and the F1
binding site.
Another group of benzodiazepines have been reported
that are structurally similar to Bz-423.35 Unlike Bz-423, these
compounds selectively inhibit ATP hydrolysis catalyzed by
the mitochondrial F1F0-ATPase and may have use as anti-
ischemia drugs. Preliminary studies suggest that these benzo-
diazepines also function through binding to the OSCP.36 To-
gether, these data highlight the important role the OSCP
plays in regulating both the synthetic and hydrolytic the
function of the mitochondrial F1F0-ATPase. A better under-
standing of how these compounds interact with the OSCP
and inhibit the enzyme should assist in further elucidating
the function of the OSCP and may also provide additional
opportunities for drug discovery.
We thank P. L. Toogood for the synthesis of 2. G.D.G. and A.W.O.
acknowledge stock ownership and consulting compensation from a
corporation that has licensed certain commercial rights to Bz-423.
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